introduct
nucleic
acid
amplif
test
nat
significantli
improv
diagnosi
acut
respiratori
tract
infect
ari
timetoresult
decreas
consider
allow
time
patient
manag
infect
control
addit
avail
nat
reduc
cost
select
situat
possibl
reduc
antibiot
usag
case
viral
infect
realtim
polymeras
chain
reaction
pcr
particular
demonstr
use
reliabl
influenza
pandem
howev
increas
number
respiratori
pathogen
diagnos
put
tremend
challeng
nat
methodolog
recent
year
new
molecular
technolog
foster
shift
singlepathogen
detect
multiplex
approach
simultan
detect
rang
respiratori
agent
inde
shown
realtim
pcr
perform
multiplex
fashion
multiplex
realtim
pcr
assay
detriment
influenc
sensit
due
complex
primerprob
interact
altern
suspens
microarray
assay
luminex
platform
allow
multipl
target
detect
singl
reaction
tube
importantli
current
avail
assay
includ
either
viral
bacteri
target
render
combin
hereof
attract
option
laboratori
sinc
viral
bacteri
infect
often
indistinguish
clinic
ground
definit
aetiolog
diagnosi
retain
utmost
import
optim
patient
care
addit
complex
interact
viral
bacteri
coinfect
demonstr
littl
inform
clinic
relev
find
streamlin
diagnost
elucid
possibl
relev
viralbacteri
coinfect
includ
bacteri
target
therefor
highli
desir
particular
atyp
bacteria
repres
reason
target
sinc
refractori
standard
cultur
techniqu
noncolonis
bacteria
within
network
academ
well
industri
partner
qiagen
therefor
develop
novel
multiplex
pcr
use
suspens
microarray
technolog
combin
detect
viral
well
atyp
bacteri
target
sympari
studi
previou
studi
shown
multiplex
suspens
microarray
outperform
tradit
techniqu
eg
direct
immunofluorescen
viru
cultur
howev
studi
combin
differ
diagnost
method
use
refer
prospect
natur
aim
studi
evalu
new
microarray
assay
pathogen
comparison
individu
realtim
pcr
realtim
pcr
assay
optimis
reach
ultim
sensit
reduc
handson
time
first
step
method
valid
panel
known
posit
archiv
sampl
hereaft
assay
deploy
prospect
collect
sampl
includ
children
adult
assess
assay
perform
nucleic
acid
extract
use
qiaamp
minelut
viru
spin
kit
qiagen
hilden
germani
qiacub
robot
qiagen
accord
manufactur
instruct
quantiti
specimen
spike
phage
lysat
pfu
per
ml
extract
elut
volum
analys
monoplex
pcr
effect
copiespcr
reaction
phage
use
similar
fashion
specimen
spike
intern
control
novel
multiplex
pcr
extract
elut
volum
analys
multiplex
pcr
extract
test
novel
multiplex
assay
qiagen
hamburg
germani
accord
manufactur
instruct
assay
compris
amplif
pathogen
dna
label
primer
follow
hybridis
pcr
product
targetspecif
captur
probe
coval
link
specif
set
colourcod
bead
revers
transcript
pcr
rtpcr
perform
use
onestep
rtpcr
kit
qiagen
hilden
germani
brief
extract
nucleic
acid
use
total
reaction
volum
includ
qiagen
onestep
rtpcr
buffer
targetspecif
multiplex
sympari
primer
mix
dntp
mix
qiagen
amplif
enhanc
qiagen
qiagen
onestep
rtpcr
enzym
mix
cycl
done
geneamp
cycler
appli
biosystem
weiterstadt
germani
follow
protocol
min
follow
min
cycl
enrich
cycl
cycl
twostep
cycl
threestep
cycl
final
extens
step
done
min
cycl
protocol
rtpcr
product
sympari
bead
mix
detect
buffer
incub
min
subsequ
conjug
mix
detect
buffer
ad
reaction
well
hereaft
reaction
incub
min
termin
reaction
stop
buffer
ad
well
detect
perform
plate
format
luminex
machin
luminex
molecular
diagnost
inc
toronto
canada
use
luminex
softwar
luminex
median
fluoresc
intens
mfi
determin
mfi
valu
threshold
level
regard
posit
multiplex
assay
simultan
detect
viral
four
bacteri
pathogen
adenoviru
human
bocaviru
hbov
human
coronavirus
cov
enteroviru
human
metapneumoviru
hmpv
univers
influenza
viru
influenza
viru
influenza
viru
influenza
viru
b
parainfluenza
viru
rhinoviru
respiratori
syncyti
viru
rsva
respiratori
syncyti
viru
b
rsvb
bordetella
pertussi
chlamydia
pneumonia
legionella
pneumophila
mycoplasma
pneumonia
result
monoplex
multiplex
pcr
analys
independ
blind
manner
two
individu
monoplex
realtim
pcr
assay
adapt
publish
method
streamlin
diagnost
assay
includ
dna
target
carri
reaction
volum
use
qiagen
onestep
rtpcr
kit
qiagen
assay
primer
concentr
primer
probe
concentr
use
revers
transcript
amplif
perform
use
roch
lightcycl
ii
system
roch
mannheim
germani
follow
cycl
profil
min
min
cycl
rna
bacteriophag
use
intern
extractioninhibit
control
concentr
copiespcr
reaction
assay
optimis
respect
maximum
sensit
specif
posit
vitro
rna
transcript
dna
plasmid
respect
target
neg
control
use
throughout
individu
assay
ctvalu
regard
posit
panel
archiv
respiratori
tract
sampl
nasopharyng
aspir
pharyng
swab
submit
depart
virolog
routin
test
use
preclin
valid
panel
compris
individu
sampl
respiratori
pathogen
avail
repositori
influenza
viru
aposit
sampl
panel
collect
influenza
pandem
compris
season
influenza
viru
clinic
sampl
avian
influenza
viru
avail
us
coronaviru
avail
due
low
preval
sampl
pretest
resplex
pcr
qiagen
hilden
germani
individu
realtim
monoplex
pcr
bacteri
target
origin
patient
materi
store
hereaft
sampl
reextract
use
method
describ
analys
realtim
monoplex
novel
multiplex
pcr
respect
respiratori
specimen
paediatr
well
adult
patient
submit
depart
virolog
includ
prospect
studi
origin
patient
sampl
aliquot
store
extract
inclus
criteria
acut
febril
lower
respiratori
tract
infect
immunocompet
patient
acut
upper
andor
lower
respiratori
tract
infect
immunocompromis
patient
respect
specimen
compris
pharyng
secret
collect
flock
swab
viral
transport
medium
copan
brescia
itali
nasopharyng
aspir
salin
solut
na
inform
consent
obtain
particip
hisher
legal
guardian
ethic
approv
obtain
freiburg
univers
medic
center
particip
studi
center
respect
data
analys
use
spss
softwar
version
spss
chicago
il
usa
openli
avail
statist
softwar
environ
r
version
data
compar
fisher
exact
test
utest
pvalu
deem
signific
level
cohen
kappa
use
assess
agreement
two
method
first
step
archiv
patient
sampl
yield
posit
result
routin
molecular
diagnost
use
preclin
valid
novel
multiplex
assay
overal
sampl
yield
concord
result
tabl
monoplex
pcrposit
sampl
display
median
ctvalu
rang
indic
broad
rang
pathogen
concentr
multiplexposit
sampl
yield
median
mfi
valu
rang
six
seven
sampl
neg
multiplex
pcr
one
human
metapneumoviru
parainfluenza
viru
parainfluenza
viru
rhinoviru
legionella
pneumophila
mycoplasma
pneumonia
respect
yield
monoplex
ctvalu
median
rang
indic
low
concentr
target
fig
multiplexneg
sampl
one
human
bocaviru
display
higher
target
gene
concentr
ctvalu
monoplex
pcr
note
sampl
yield
correspond
mfi
valu
slightli
posit
threshold
multiplex
pcr
mfi
exclus
weakli
posit
sampl
monoplex
pcr
ctvalu
analysi
would
increas
overal
detect
rate
multiplex
pcr
next
step
total
clinic
sampl
prospect
collect
total
patient
contribut
singl
sampl
patient
contribut
two
sampl
independ
ari
episod
mean
median
age
patient
year
respect
adult
contribut
sampl
paediatr
patient
contribut
sampl
adult
patient
immunocompet
wherea
immunocompromis
paediatr
patient
immunocompet
immunocompromis
collect
sampl
compris
nasopharyng
aspir
pharyng
swab
sampl
exact
inform
time
symptom
onset
sampl
avail
median
time
onset
acut
respiratori
symptom
sampl
day
confid
interv
ci
day
monoplex
pcr
detect
pathogen
sampl
singl
infect
observ
sampl
expect
posit
rate
significantli
higher
paediatr
patient
compar
adult
fisher
exact
test
p
note
time
symptom
onset
sampl
differ
monoplex
pcrposit
neg
sampl
utest
p
frequent
identifi
pathogen
rhinoviru
detect
follow
rsvb
hmpv
detect
least
detect
pathogen
enteroviru
legionella
pneumophila
parainfluenza
viru
coronaviru
detect
respect
season
influenza
virus
influenza
viru
b
bordetella
pertussi
detect
within
studi
group
sampl
bacteri
pathogen
identifi
mycoplasma
pneumonia
frequent
tabl
multipl
detect
pathogen
occur
sampl
almost
exclus
paediatr
patient
median
age
year
ci
year
except
one
studi
subject
two
specimen
harbour
five
six
differ
pathogen
respect
howev
major
multipleposit
sampl
dual
infect
tabl
rhinoviru
copathogen
frequent
detect
follow
human
bocaviru
rsvb
parainfluenza
viru
cov
bordetella
pertussi
legionella
pneumophila
involv
multipl
infect
final
phage
serv
intern
control
detect
sampl
indic
robust
assay
overal
multiplex
pcr
yield
posit
result
sampl
experienc
monoplex
pcr
significantli
sampl
posit
paediatr
patient
compar
adult
fisher
exact
test
p
frequent
detect
pathogen
multiplex
pcr
rhinoviru
follow
rsvb
human
metapneumoviru
rsva
respect
least
detect
pathogen
parainfluenza
viru
coronaviru
chlamydia
pneumonia
singl
detect
respect
season
influenza
virus
influenza
viru
b
coronaviru
bordetella
pertussi
legionella
pneumophila
found
notabl
version
multiplex
assay
design
type
pandem
influenza
viru
instead
detect
pandem
influenza
viru
achiev
exclus
criteria
posit
result
univers
influenza
viru
concomitantli
neg
season
henc
sampl
posit
univers
influenza
viru
neg
season
influenza
viru
indic
presenc
pandem
find
confirm
upon
use
specif
realtim
pcr
multipl
detect
detect
record
sampl
three
agent
frequent
detect
multiplex
pcr
subgroup
rhinoviru
rsvb
human
bocaviru
respect
season
influenza
viru
influenza
viru
b
coronaviru
parainfluenza
viru
chlamydia
pneumonia
bordetella
pertussi
detect
intern
control
multiplex
assay
yield
valid
signal
sampl
detect
randomli
occur
first
sampl
could
attribut
process
error
correct
ie
use
recommend
concentr
intern
control
valid
signal
obtain
sampl
common
pathogen
sensit
rang
specif
rang
respect
tabl
sinc
preval
viral
well
bacteri
pathogen
rather
low
sensit
specif
could
reliabl
assess
posit
neg
predict
valu
ppv
npv
rang
respect
cohen
kappa
calcul
rang
fair
perfect
tabl
howev
common
pathogen
yield
kappa
valu
ci
indic
substanti
rhinoviru
hmpv
human
bocaviru
almost
perfect
agreement
rsva
rsvb
analysi
patient
sampl
level
yield
concord
result
ci
sampl
sampl
discrep
result
show
falseposit
deviat
falseneg
deviat
direct
discrep
result
includ
broad
varieti
pathogen
discrep
result
observ
rhinoviru
total
falseneg
falseposit
result
follow
rsvb
ten
nine
falseneg
one
falseposit
result
hmpv
nine
eight
falseneg
one
falseposit
result
human
bocaviru
nine
discrep
result
nine
falseneg
result
respect
interestingli
falseneg
sampl
significantli
lower
target
gene
concentr
indic
higher
ctvalu
record
bocaviru
hmpv
rsvb
parainfluenza
viru
rhinoviru
mycoplasma
pneumonia
tabl
analys
rhinoviru
discrep
result
sequenc
gene
nine
monoplexpositivemultiplexneg
eight
monoplexnegativemultiplexposit
sampl
total
sampl
compris
novel
rhinoviru
type
c
demonstr
sequenc
analysi
data
shown
monoplexpositivemultiplexneg
group
sampl
yield
novel
rhinoviru
c
wherea
monoplexnegativemultiplexposit
group
sampl
posit
rhinoviru
c
respect
note
three
rhinovirusposit
sampl
concord
result
monoplex
pcrposit
multiplex
pcrposit
concomitantli
yield
falseposit
enteroviru
signal
multiplex
pcr
howev
correspond
enteroviru
mfi
valu
sampl
lower
rhinoviru
mfi
valu
indic
possibl
crossreact
enteroviru
assay
final
comparison
patient
sampl
level
sampl
multipl
detect
show
sampl
yield
concord
result
dual
infect
one
tripl
infect
analys
sampl
ctvalu
monoplex
pcrposit
sampl
dual
detect
compar
respect
concord
discord
multiplex
result
pathogen
categoris
high
target
gene
concentr
low
target
gene
concentr
pathogen
base
ctvalu
monoplex
pcr
tabl
pathogen
median
ctvalu
discord
sampl
wherea
concord
sampl
yield
median
ctvalu
utest
p
similar
fashion
pathogen
median
ctvalu
respect
utest
p
novel
microarray
pcr
develop
detect
pathogen
caus
acut
febril
respiratori
tract
infect
technic
standpoint
incorpor
viral
four
bacteri
target
singl
multiplex
assay
success
demonstr
panel
previous
characteris
sampl
fulli
appreci
role
virus
ari
decid
includ
virus
current
associ
ari
includ
broad
rang
pathogen
one
assay
provid
opportun
studi
relev
multipl
infect
possibl
interact
ari
pathogen
recent
studi
point
clinic
relev
issu
decid
includ
atyp
bacteria
bordetella
pertussi
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
pneumophila
panel
sinc
noncolonis
bacteria
hard
cultiv
thu
provid
valuabl
target
molecular
assay
previou
studi
alreadi
demonstr
feasibl
nat
detect
atyp
bacteria
formalinfix
paraffinembed
specimen
infect
mycoplasma
pneumonia
associ
sever
ill
cohort
children
test
might
also
valu
risk
assess
interestingli
brunstein
et
al
report
infectivityenhanc
activ
pneumonia
h
influenza
sinc
combin
influenza
concurr
infect
pneumonia
worsen
outcom
inclus
pneumonia
panel
might
futur
option
howev
asymptomat
colonis
pneumonia
occur
may
limit
valid
posit
pcr
result
gener
molecular
detect
method
rapid
identif
ari
pathogen
outperform
classic
method
numer
studi
therefor
includ
classic
method
like
direct
fluoresc
antigen
dfa
detect
viru
isol
test
algorithm
instead
panel
publish
optimis
monoplex
pcr
assay
use
comparison
use
individu
realtim
pcr
assay
also
allow
reliabl
estim
rel
target
gene
concentr
direct
comparison
patient
sampl
level
use
monoplex
pcr
gold
standard
show
concord
result
ci
sampl
sensit
vari
across
target
similar
find
report
gadsbi
et
al
compar
xtag
respiratori
viral
panel
rvp
inhous
realtim
pcr
low
number
posit
sampl
certainli
limit
valid
target
requir
larger
studi
order
reliabl
assess
sensit
specif
similar
gadsbi
et
al
found
discrep
result
associ
ctvalu
seen
viral
well
bacteri
target
note
except
rhinoviru
parainfluenza
viru
mycoplasma
pneumonia
find
like
associ
sequenc
mismatch
primer
target
rather
low
target
gene
concentr
howev
although
microarray
assay
present
technic
optimis
inclus
addit
target
might
detriment
outcom
sensit
limit
approach
use
monoplex
pcr
gold
standard
nondetect
variant
viru
encount
eg
rhinoviru
resolut
subset
discrep
result
rhinoviru
show
novel
rhinoviru
c
influenc
perform
refer
method
well
novel
multiplex
test
recent
faux
et
al
compar
differ
rhinoviru
pcr
assay
report
high
degre
variabl
perform
support
find
present
likewis
molecular
method
detect
adenoviru
challeng
due
rang
differ
type
particular
gadsbi
et
al
report
fairli
low
sensit
xtag
rvp
assay
adenoviru
like
attribut
primer
mismatch
studi
sensit
adenoviru
assay
rather
good
valu
unlik
one
type
detect
sinc
specimen
prospect
collect
period
differ
studi
site
still
without
sequenc
remain
unclear
adenoviru
serotyp
preval
studi
importantli
adult
especi
may
benefit
highli
sensit
molecular
method
sinc
shed
ari
pathogen
lower
multipl
children
howev
adult
cohort
observ
detect
rate
studi
slightli
lower
report
pabbaraju
et
al
remain
specul
whether
find
might
attribut
part
differ
sampl
type
use
light
lower
detect
rate
adult
patient
applic
novel
microarray
assay
might
restrict
younger
patient
larger
studi
among
adult
popul
may
clarifi
method
test
algorithm
sensit
feasibl
approach
use
panel
target
may
also
prove
costeffect
sinc
turnaround
time
decreas
consider
compar
mix
cultur
dfa
select
pcr
test
noncultivat
agent
novel
multiplex
pcr
gener
result
within
h
complet
singl
work
day
mahoni
et
al
shown
multiplex
pcr
least
costli
option
cohort
children
howev
result
highli
depend
preval
pathogen
thu
might
appli
adult
bacteri
target
lower
sensit
observ
similar
find
benson
et
al
critic
number
sampl
adequ
target
thu
limit
valid
result
nevertheless
number
bacteri
infect
detect
method
studi
may
valuabl
guid
clinician
decis
initi
specif
treatment
note
legionella
pneumophila
remain
undetect
studi
rule
pharyng
specimen
optim
specimen
type
use
sputum
might
provid
better
result
better
standardis
howev
decid
collect
one
specimen
type
per
patient
studi
one
strength
multiplex
pcr
abil
detect
multipl
infect
contrast
convent
test
specimen
perform
sequenti
manner
stop
first
posit
result
posit
result
threshold
pcr
reaction
commun
clinician
recent
studi
rand
et
al
demonstr
mix
infect
cohort
patient
observ
multipl
infect
slightli
lower
preval
respect
howev
clinic
signific
dual
tripl
infect
remain
unclear
date
interestingli
rna
virus
frequent
associ
multipl
infect
wherea
viralbacteri
combin
rare
seen
note
realtim
pcr
significantli
sensit
detect
multipl
infect
wherea
multiplex
assay
frequent
miss
second
pathogen
instanc
due
low
target
gene
concentr
indic
ctvalu
monoplex
pcr
futur
prospect
measur
target
gene
concentr
similarli
cytomegaloviru
cmv
bk
viru
bkv
dna
quantif
might
interest
option
shown
franz
et
al
studi
symptomat
patient
display
significantli
higher
pathogen
concentr
asymptomat
control
moreov
suggest
eg
length
therapi
could
base
quantit
data
howev
correl
mfi
valu
target
gene
concentr
firmli
assess
multiplex
beadbas
assay
anoth
issu
concern
sampl
respiratori
specimen
far
standardis
optim
specimen
type
need
determin
might
vari
differ
agent
data
clinic
relev
viru
detect
bronchoalveolar
lavag
bal
specimen
desir
conclud
present
novel
multiplex
assay
detect
viral
well
bacteri
pathogen
associ
febril
ari
assay
prove
princip
current
evalu
larg
prospect
multicentr
trial
ari
also
initi
hypothesi
approach
might
instrument
reduc
unjustifi
antibiot
usag
